Switzerland's trade agreement with India has entered its second year with different results across industries. An October review by SWI swissinfo.ch reported benefits for machinery and watches, while pharmaceutical businesses continued to seek stronger intellectual-property protection. The agreement opens a preferential route into India, but access depends on the product and does not settle every regulatory question.1
The report describes renewed bilateral intellectual-property discussions during the Swiss president's October visit. It also distinguishes announced investment from benefits already realised: Roche said its planned expansion supported existing Indian operations, while it had not yet observed tangible benefits for imported medicines. That makes investment commitments a different measure from additional shipments of Swiss-made drugs.1
The coverage figure excludes gold
Switzerland's economic affairs secretariat says the agreement improves access for 94.7% of previous exports, measured over 2018–2023 and excluding gold. The covered categories include machinery, medicines, optical instruments, watches and processed agricultural products. Its estimate of annual duty savings of up to CHF167 million applies after transition periods, using existing trade as the calculation base.2
The government presents the agreement as a means to:
neue Märkte zu erschliessen und sich so zu diversifizieren.
Open new markets and diversify.2
That is the stated policy objective. The published estimate does not measure savings already received by every exporter during the agreement's opening year.2
The supply chain must support the origin claim
Swiss customs guidance limits origin cumulation to qualifying goods from the EFTA countries and India. Inputs from another free-trade partner cannot automatically acquire qualifying status through that separate agreement. This matters for manufacturers sourcing components internationally: the preferential rate depends on satisfying the relevant product rule.3
The guidance permits consignments to pass through a third country, including transshipment and splitting, provided they remain under customs control and are not further processed beyond permitted preservation measures. Swiss authorised exporters can use an electronically signed origin declaration; other exporters use the designated movement certificate. These requirements concern the evidence accompanying the goods, even where the commercial customer and final destination are already known.3
India is seeking manufacturing partnerships
India's commerce ministry said officials reviewing implementation in Switzerland on 6–7 May 2026 discussed regulatory cooperation, non-tariff barriers and early resolution of practical problems. Its account emphasised attracting Swiss investment into pharmaceuticals, biotechnology, precision engineering, clean energy and other manufacturing sectors. Those discussions concern production partnerships as well as market access for finished goods.4
The ministry reported Indian goods exports to Switzerland exceeding US$1.2 billion in the 2025–26 financial year. This is a flow in the opposite direction from Swiss exports and cannot establish the agreement's effect on Swiss factory output. The ministry said the agreement's eventual success should be assessed through exports, investment, jobs and technology partnerships. The remaining implementation question is how those commercial outcomes develop beyond announced access and investment intentions.4